Skip to main content

Table 3 Hazard ratios of use of statin and fibrate for risk of cardiovascular disease in Chinese type 2 diabetic patients

From: Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study

Exposures HR 95%CI P value
In the entire cohort§†    
Use of statins during follow-up 0.66 0.50 to 0.88 .0038
Use of fibrates during follow-up 0.61 0.37 to 1.03 .0640
In the sub-cohort with LDL-C < 3.0 mmol/L¶, §    
Use of statins during follow-up 1.10 0.56 to 2.16 .7798
Use of fibrates during follow-up 0.34 0.12 to 1.00 .0495
In the sub-cohort with LDL-C ≥ 3.0 mmol/L¶, §    
Use of statins during follow-up 0.60 0.44 to 0.82 .0012
Use of fibrates during follow-up 0.65 0.35 to 1.19 .1590
In the sub-cohort with HDL-C < 1.0 mmol/L in male or 1.3 mmol/L in female ζ, §    
Use of statins during follow-up 0.49 0.28 to 0.88 .0162
Use of fibrates during follow-up 0.37 0.13 to 1.09 .0703
In the sub-cohort with HDL-C ≥1.0 mmol/L in male or ≥ 1.3 mmol/L in female ζ, §    
Use of statins during follow-up 0.73 0.53 to 1.02 .0662
Use of fibrates during follow-up 0.74 0.41 to 1.35 .3303
In the sub-cohort with metabolic syndrome at baseline ‡,§    
Use of statins during follow-up 0.58 0.42 to 0.80 .0010
Use of fibrates during follow-up 0.60 0.35 to 1.05 .0713
In the sub-cohort without metabolic syndrome at baseline ‡,§    
Use of statins during follow-up 0.77 0.42 to 1.44 .4201
Use of fibrates during follow-up 0.57 0.12 to 2.73 .4903
  1. †Adjusted for LDL-C (≥ 3.0 mmol/L vs. < 3.0 mmol/L), HDL-C, triglyceride, age, smoking status, duration of diabetes, HbA1c, Ln (ACR + 1), gliclazide and rosiglitazone during follow-up, years of enrolment (selected by the stepwise algorithm with P = .10 for entry and stay);
  2. Adjusted for the variables listed in ‡, except for LDL-C;
  3. ζ, Adjusted for the variables listed in ‡, except for HDL-C;
  4. §, Cox models stratified on deciles of probability of initiation of statin therapy during follow-up and on deciles of probability of initiation of fibrate therapy during follow-up.